number
monoclon
antibodi
mab
base
drug
develop
biopharmaceut
compani
alltim
high
novel
antiinfect
antibodi
gain
regulatori
approv
emerg
multidrug
resist
reinforc
need
develop
novel
antiinfect
approach
unlik
convent
antibiot
monoclon
antibodi
exhibit
high
target
specif
possess
abil
recruit
immun
system
compon
effect
pathogen
remov
mode
action
includ
specif
bind
neutralis
microbi
toxin
virul
factor
opsonis
mark
pathogen
celldeath
direct
phagocyt
cell
site
infect
antibodi
mediat
bacteri
agglutin
clearanc
complement
activ
direct
bacteri
lysi
host
effector
function
mediat
interact
fc
region
mab
drug
make
highli
effect
treat
immunocompromis
patient
unabl
gener
immun
respons
fight
diseas
certain
monoclon
antibodi
exhibit
synergist
addit
effect
convent
antibiot
provid
attract
therapeut
strategi
treat
infect
caus
multidrug
resist
organ
chapter
discuss
advantag
disadvantag
use
immunis
phage
display
librari
construct
mammalian
sourc
gener
monoclon
antibodi
infecti
diseas
target
sever
group
success
develop
monoclon
antibodi
specif
bacteri
fungal
viral
antigen
potenti
applic
detect
diagnosi
treatment
infecti
diseas
review
chapter
origin
mab
isol
use
hybridoma
technolog
requir
fusion
mous
lymphocyt
myeloma
cell
gener
specif
murin
antibodi
often
highli
immunogen
use
therapeut
set
limit
number
human
mab
also
develop
use
human
b
lymphocyt
natur
infect
patient
prove
technic
challeng
gener
unreli
approach
subsequ
advanc
antibodi
engin
remov
resolv
mani
technolog
roadblock
facilit
gener
chimer
humanis
deimmunis
mab
bispecif
antibodi
increas
potenc
reduc
immunogen
one
major
breakthrough
invent
phage
display
revolutionis
field
antibodi
engin
robust
easi
use
highli
versatil
combinatori
display
platform
success
applic
includ
gener
antibodi
uniqu
function
immun
nonimmun
sourc
de
novo
isol
high
affin
binder
nonimmun
synthet
sourc
vitro
affin
matur
antibodi
phage
base
select
could
summaris
display
antibodi
protein
peptid
surfac
bacteriophag
fuse
antibodi
gene
one
phage
coat
protein
select
base
antigen
bind
individu
clone
phage
antibodi
librari
construct
pcr
base
clone
vh
vl
repertoir
random
pair
phage
phagemid
vector
system
display
surfac
bacteriophag
use
wide
antibodi
engin
techniqu
mimic
b
cell
selfrepl
packag
system
contain
antibodi
gene
encod
antibodi
display
surfac
link
genotyp
phenotyp
phage
display
librari
construct
use
antibodi
variabl
v
gene
isol
igm
mrna
nonimmunis
human
donor
b
cell
deriv
divers
lymphoid
sourc
peripher
blood
lymphocyt
pbl
spleen
cell
tonsil
bone
marrow
nonimmunis
anim
b
cell
antibodi
librari
igg
mrna
pbl
spleen
cell
immunis
anim
human
patient
use
build
immunis
librari
third
class
call
synthet
semisynthet
antibodi
librari
construct
use
repertoir
rearrang
v
gene
gene
segment
use
polymeras
chain
reaction
pcr
introduc
variat
cdr
region
use
custom
degener
primer
encod
divers
length
immunis
librari
gener
construct
use
antibodi
vh
vl
gene
amplifi
mrna
b
cell
pool
immunis
anim
human
donor
post
immunis
antibodi
secret
b
cell
possess
higher
percentag
antigen
specif
heavi
light
chain
gene
transcript
b
cell
would
undergon
affin
matur
isotyp
switch
germin
centr
enter
peripher
circul
typic
antibodi
isol
immunis
librari
high
affin
tighter
specif
immunogen
use
achiev
even
rel
small
librari
divers
unlik
hybridoma
technolog
phage
display
provid
research
possibl
streamlin
monoclon
antibodi
gener
process
main
improv
replac
cell
cultur
screen
step
use
hybridoma
instead
screen
hundr
thousand
hybridoma
monoclon
find
posit
clone
phage
display
care
design
pan
strategi
screen
billion
clone
allow
enrich
small
subset
binder
desir
characterist
screen
identifi
individu
binder
antibodi
recognis
specif
antigen
conform
epitop
easili
isol
introduc
select
subtract
pan
step
select
process
also
report
use
phage
display
high
specif
antibodi
isol
immunis
sourc
would
miss
tradit
immunolog
method
key
featur
system
linkag
genotyp
phagemid
vector
phenotyp
phage
coat
protein
antibodi
fragment
allow
immedi
access
correspond
gene
sequenc
select
antibodi
facilit
simpl
subclon
variou
antibodi
format
base
requir
downstream
applic
fig
last
year
phage
display
technolog
success
use
develop
mani
therapeut
antibodi
candid
approv
drug
relax
commerci
restrict
product
enter
diagnost
research
market
well
drawback
anim
immunis
construct
phage
display
librari
includ
time
period
requir
complet
process
requir
construct
separ
librari
antigen
howev
combin
power
immunis
phage
display
sever
high
affin
monoclon
antibodi
difficult
antigen
target
isol
rel
small
antibodi
librari
tradit
approach
fail
gener
antibodi
self
toxic
antigen
limit
immunis
employ
particular
human
autoantigen
highli
conserv
amongst
routin
use
laboratori
mammal
mice
rat
therefor
immunis
nonmamm
shark
chicken
phylogenet
distant
human
success
employ
gener
immun
respons
antibodi
andor
antibodi
like
binder
vnar
epitop
conserv
mammalian
speci
chicken
phylogenet
distant
human
therefor
success
gener
immun
respons
mammalian
protein
highli
conserv
shark
even
distant
human
diverg
common
ancestor
approxim
million
year
ago
phage
display
librari
construct
immun
sera
bone
marrow
cell
collect
infect
patient
use
isol
neutralis
antibodi
viral
infect
human
monoclon
antibodi
select
recognis
differ
strain
influenza
viru
ebola
viru
hiv
herp
simplex
viru
rabi
hepat
b
success
isol
immun
human
phage
display
librari
potenti
diagnosi
therapi
human
monoclon
antibodi
patient
show
protect
effect
anim
model
studi
also
select
bacteri
target
anthrax
toxin
botulinum
neurotoxin
abc
transport
methicillin
resist
staphylococcu
aureu
case
west
nile
viru
neutralis
mab
isol
b
cell
popul
convalesc
human
patient
larg
phage
display
librari
construct
uninfect
donor
deliv
noth
consequ
convent
method
antibodi
gener
hybridoma
epsteinbarr
viru
transform
limit
abil
evalu
human
monoclon
antibodi
differ
patient
variou
stage
clinic
cours
technolog
like
phage
display
provid
power
tool
allow
pool
larg
number
patient
immun
b
cell
popul
select
antibodi
distinct
specif
inhibitori
activ
differ
stage
infect
abil
improv
affin
broaden
specif
post
select
major
attribut
recombin
antibodi
use
recombin
dna
protein
engin
approach
pharmacokinet
pharmacodynam
properti
molecul
improv
includ
halflif
extens
reduc
immunogen
neutralis
toxin
virus
often
advantag
gener
multipl
high
affin
antibodi
recognis
differ
epitop
antigen
varieti
antigen
subtyp
capabl
deliv
broad
protect
pathogen
variant
oligoclon
antibodi
report
show
strong
synergist
activ
neutralis
botulinum
neurotoxin
bont
assay
list
recombin
antibodi
gener
phage
display
librari
construct
use
immun
antibodi
gene
repertoir
human
patient
given
tabl
infect
control
use
high
affin
monoclon
antibodi
specif
target
quorum
sens
qs
molecul
pseudomona
aeruginosa
report
laboratori
number
gram
neg
bacteria
includ
pathogen
like
p
aeruginosa
utilis
homoserin
lacton
hsl
qs
signal
compound
engag
celltocel
commun
coordin
behaviour
qs
take
central
role
p
aeruginosa
infect
regul
express
extracellular
virul
factor
also
biofilm
format
immunomodul
hsl
molecul
monoclon
antibodi
mab
use
novel
approach
prevent
p
aeruginosa
infect
sheep
immunis
utilis
develop
antibodi
high
affin
sensit
toward
hsl
compound
mixtur
three
differ
subgroup
third
carbon
posit
conjug
carrier
protein
thyroglobulin
tg
use
immunogen
enhanc
chanc
elicit
antibodi
respons
sheep
use
pbl
immunis
sheep
start
materi
antihsl
phage
display
librari
construct
scfv
format
pan
strategi
design
drive
select
toward
enrich
high
sensit
crossreact
clone
lead
clone
reformat
sheepmous
chimer
igg
picomolar
sensit
valu
determin
competit
elisa
central
qs
compound
p
aeruginosa
valu
quit
impress
consid
chemic
natur
lipidlik
compound
averag
molecular
weight
da
possess
small
head
like
structur
lack
critic
antigen
featur
aromat
charg
model
sensit
antihsl
antibodi
indic
level
sensit
observ
achiev
gener
deep
neg
charg
bind
pocket
sheep
immunis
chosen
hsl
applic
approach
previous
shown
gener
high
affin
antibodi
hapten
target
sheep
polyclon
antibodi
use
specif
high
affin
immunolog
probe
analyt
clinic
purpos
mani
year
contrast
human
mice
sheep
b
cell
lymphopoiesi
occur
predominantli
ileal
peyer
patch
ipp
v
j
recombin
creat
limit
divers
sheep
ig
repertoir
due
gene
segment
particip
rearrang
process
characterist
featur
make
sheep
librari
construct
simpler
entir
heavi
light
chain
gene
repertoir
amplifi
use
small
number
primer
much
antibodi
divers
achiev
antigenindepend
postrearrang
somat
hypermut
diversifi
cdr
compar
sole
variabl
human
mice
comparison
chicken
sheep
respons
hyperimmunis
immunogen
reveal
abil
sheep
immun
system
produc
higher
specif
antibodi
chicken
overal
antibodi
titr
also
much
higher
sheep
might
due
longer
halflif
day
sheep
immunoglobulin
compar
h
chicken
also
noteworthi
sensit
sheep
polyclonalmab
antibodi
describ
far
superior
publish
mous
monoclon
antibodi
specif
hsl
antigen
protect
effect
sheep
deriv
antiquorum
sens
antibodi
demonstr
vivo
slow
kill
model
nematod
worm
caenorhabd
elegan
signific
increas
surviv
rate
presenc
hsl
mab
similar
defect
slow
kill
observ
lasr
mutant
strain
furthermor
nonneutropen
lung
model
mice
infect
p
aeruginosa
hsl
mab
monotherapi
demonstr
signific
efficaci
prolong
surviv
sinc
signific
reduct
bacteri
count
observ
lung
infect
mice
propos
hsl
specif
antibodi
protect
mice
possibl
antibodi
mediat
scaveng
hsl
compound
mode
action
necessarili
affect
bacteri
number
probabl
prevent
switch
pathogen
phenotyp
wide
accept
antibodi
subnanomolar
affin
exhibit
improv
therapeut
efficaci
target
bound
present
low
concentr
studi
demonstr
power
anim
immunis
phage
display
base
select
strategi
isol
high
affin
monoclon
antibodi
toward
nonantigen
target
inher
lack
properti
like
aromat
charg
adpribosyl
enzym
cholera
pertussi
diphtheria
toxin
escherichia
coli
heatlabil
lt
toxin
import
virul
factor
number
extracellular
bacteri
pathogen
pathogenesi
driven
secret
potent
toxin
utilis
adpribosyl
catalyt
mechan
underli
action
adpribosyl
toxin
compris
larg
famili
produc
diseas
alter
key
metabol
process
transfer
adpribos
moieti
nad
specif
hostcel
target
protein
earli
adpribosyl
enzym
implic
intracellular
pathogenesi
shown
salmonella
strain
capabl
invad
epitheli
cell
localis
macrophag
infect
salmonella
virul
plasmid
factor
b
spvb
virul
gene
salmonella
requir
human
macrophag
cytotox
vitro
enhanc
intracellular
bacteri
prolifer
infect
lesnick
et
al
provid
evid
spvb
encod
adpribosyl
enzym
use
actin
substrat
depolymeris
actin
filament
express
cho
cell
spvb
block
camel
vhh
singl
domain
antibodi
sdab
capabl
block
spvb
enzymat
activ
molar
ratio
isol
immun
phage
display
librari
gener
spvb
immunis
llama
intracellular
protein
spvb
inaccess
convent
antibodi
small
molecul
inhibitor
spvb
fraught
potenti
side
effect
result
indiscrimin
inhibit
endogen
mammalian
adpribosyltransferas
art
vhh
sdab
express
intrabodi
effect
protect
cell
cytotox
activ
translocationcompet
chimer
toxin
transfect
cell
also
protect
cytoskelet
alter
induc
wildtyp
spvbexpress
strain
salmonella
provid
evid
support
develop
sdab
therapeut
experiment
tool
block
mammalian
toxin
art
helicobact
pylori
gram
neg
pathogen
bacteria
colonis
human
stomach
caus
gastriti
gastric
duoden
ulcer
cancer
surfac
protein
h
pylori
mediat
sever
hostpathogen
interact
henc
attract
target
antimicrobi
therapi
vaccin
antibodi
phage
display
librari
scfv
format
construct
hyperimmunis
mice
h
pylori
total
cell
lysat
monoclon
antibodi
fragment
recognis
outer
membran
protein
hopq
isol
perform
biopan
whole
cell
anoth
studi
mab
gener
mice
immunis
hybridoma
technolog
engin
use
phagedisplay
scfv
fragment
show
high
affin
bind
h
pylori
surfac
antigen
phage
display
scfv
antibodi
shown
inhibit
growth
six
differ
h
pylori
strain
offer
signific
protect
mous
model
infect
author
argu
genet
engin
bacteriophag
could
use
altern
convent
antibiot
treatment
bacteri
infect
spleen
sampl
mice
immunis
gamma
inactiv
brucella
melitensi
strain
bacteria
use
construct
phage
display
librari
isol
monoclon
antibodi
fragment
specif
recognis
brucella
speci
brucella
caus
long
term
debilit
ill
human
spread
aerosol
surviv
extend
period
outsid
host
attribut
could
make
brucella
speci
possibl
biolog
warfar
agent
sinc
mani
brucella
speci
share
immunodomin
lipopolysaccharid
lp
antigen
close
relat
yersinia
speci
specif
lp
antibodi
distinguish
two
bacteria
central
rapid
detect
diagnosi
brucella
infect
specif
wash
step
includ
bio
pan
immunis
b
melitensi
librari
elimin
phage
might
crossreact
strain
express
domin
lp
epitop
yersinia
result
monoclon
antibodi
fragment
specif
antigen
crossreact
toward
yersinia
speci
variabl
region
vhh
heavi
chain
antibodi
hcab
found
camelida
speci
possess
unusu
long
complementar
determin
region
form
fingerlik
extens
penetr
groov
surfac
antigen
usual
inaccess
convent
antibodi
staphylococcu
aureu
produc
sever
adhes
factor
exotoxin
hemolysin
leukocidin
pvl
import
virul
determin
aureu
lead
caus
endophtalm
associ
poor
visual
outcom
express
pvl
leucotoxin
especi
lukspv
lukfpv
induc
activ
permeabilis
target
cell
result
cell
lysi
transgen
mice
harbour
llamahuman
hybrid
ig
heavi
chain
locu
immun
recombin
lukspv
lukfpv
protein
use
phage
display
technolog
high
affin
vhh
isol
reformat
bival
tetraval
camel
heavi
chain
antibodi
anti
lukspv
lukfpv
hcab
abl
inhibit
pvl
associ
diseas
patholog
noninfecti
model
rabbit
intravitr
pvl
administ
prophylact
hcab
complet
reduc
inflamm
eye
treatment
group
without
appar
damag
vision
behaviour
show
possibl
administ
toxin
neutralis
antibodi
combin
intravitr
antimicrobi
strategi
postsurgeri
endophthalm
camel
immunis
use
aureu
exoprotein
success
gener
anti
hemolysin
singl
domain
antibodi
report
jangra
singh
neutralis
assay
lead
vhh
clone
complet
inhibit
five
hemolyt
unit
toxin
vitro
resist
thermal
denatur
loop
vhh
longer
averag
igg
link
interloop
disulphid
bond
render
addit
stabil
protein
case
long
loop
enabl
format
convex
paratop
access
deep
enzymat
cleft
caviti
surfac
antigen
activ
site
enzym
hemolysin
mostli
situat
largest
cleft
long
loop
anti
hemolysin
clone
believ
bind
site
abl
neutralis
enzym
activ
block
access
hlb
antigen
vhh
fragment
specif
bind
tetanu
toxoid
antigen
gener
use
camel
immunis
phage
display
technolog
two
vhh
fragment
recognis
two
differ
epitop
antigen
success
neutralis
tetanu
toxin
vivo
studi
conduct
mice
anoth
exampl
vhh
inhibit
bacteri
infect
increas
bacteri
sensit
antibiot
report
high
affin
inhibit
vhh
gener
immunis
dromedari
phage
display
librari
prime
toward
antigen
bciilactamas
repres
class
class
blactamas
respect
presenc
ampicillin
specif
vhh
fragment
inhibit
growth
e
coli
cell
express
fusion
protein
outer
surfac
wherea
cell
abl
grown
higher
concentr
ampicillin
vhh
fragment
ad
author
claim
vhh
less
immunogen
larger
murin
antibodi
show
high
sequenc
similar
human
vh
famili
vhh
nanobodi
dose
ngkg
capabl
neutralis
bont
challeng
mice
gener
immun
phage
display
librari
oneyearold
male
dromedari
camelu
dromedari
immunis
purifi
recombin
bont
protein
anoth
high
affin
vhh
inhibitor
bonta
proteas
activ
isol
phage
display
librari
deriv
b
cell
obtain
immunis
alpaca
lama
paco
one
main
advantag
use
anim
immunis
phage
display
librari
gener
antibodi
bacteri
antigen
easi
isol
high
affin
neutralis
antibodi
without
need
affin
matur
tabl
summaris
monoclon
antibodi
antibodi
fragment
variou
bacteri
target
affin
target
antigen
eukaryot
natur
fungal
pathogen
present
almost
insurmount
problem
develop
antifung
drug
multipl
drug
resist
associ
exist
chemic
antifung
drug
highlight
need
new
effect
antifung
therapi
antibodi
base
antifung
treatment
provid
much
need
altern
nearexhaust
chemic
base
strategi
due
high
specif
target
select
antifung
antibodi
success
employ
target
kill
fungal
pathogen
without
harm
host
cell
use
hybridoma
technolog
sever
mab
gener
variou
antigen
compon
fungal
pathogen
cryptooccu
neoforman
candida
albican
aspergillu
fumigatu
pneumocysti
jerovecii
histoplasma
capsulatum
murin
monoclon
antibodi
mab
gener
hybridoma
technolog
direct
capsular
polysaccharid
c
neoforman
mediat
protect
murin
model
infect
shown
safe
use
human
patient
phase
dose
escal
studi
addit
classic
antibodi
mediat
mechan
phagocytosi
complement
activ
recruit
inflammatori
cell
mab
shown
increas
stiff
capsul
polysaccharid
cross
linkag
impair
yeast
bud
trap
newli
emerg
bud
insid
parent
capsul
opportunist
invas
fungal
pathogen
caus
million
lifethreaten
infect
per
year
worldwid
mortal
rang
common
caus
invas
fungal
infect
intens
care
unit
candida
spp
usa
western
europ
incid
candida
infect
second
staphylococcu
aureu
includ
mrsa
recent
data
indic
incid
candidaemia
continu
rise
uncheck
current
clinic
practic
drug
regimen
candida
mannan
specif
monoclon
antibodi
gener
sheep
immunis
laboratori
singl
chain
antibodi
phage
display
librari
construct
use
immun
repertoir
sheep
hyperimmunis
candida
albican
hyphal
cell
wall
prepar
antibodi
librari
one
first
largest
candida
cell
wall
antigen
success
use
isol
high
affin
specif
binder
candida
typic
poorli
immunogen
glycan
present
fungal
cell
surfac
analysi
via
sem
polyclon
sera
deriv
immunis
sheep
confirm
librari
contain
vari
collect
antibodi
specif
fungal
cell
wall
carbohydr
mannan
glucan
well
number
import
cell
wall
protein
patent
killer
toxin
protein
secret
yeast
stop
growth
compet
strain
inhibit
transmembran
enzym
glucan
synthas
involv
cell
wall
synthesi
neutralis
monoclon
antibodi
gener
toxin
use
immunis
mice
isol
antiidiotyp
antibodi
scfv
phage
display
librari
construct
use
mice
spleenocyt
antiidiotyp
scfv
fragment
inhibit
synthas
activ
isol
librari
show
vitro
cell
kill
four
pathogen
speci
candida
includ
c
albican
c
tropicali
c
parapsilosi
c
glabrata
mic
valu
scfv
rang
biopan
use
aspergillu
fumigatu
membran
fraction
amf
employ
competit
pan
elut
method
scfv
clone
show
vitro
antifung
activ
fumigatu
isol
librari
author
argu
potenti
scfv
candid
develop
antifung
drug
either
engin
scfvdrug
conjug
reformat
whole
igg
complementmedi
antibodydepend
cytotox
pathway
number
human
antibodi
fragment
recognis
c
albican
cell
surfac
antigen
isol
human
phage
display
librari
beyond
scope
review
author
demonstr
antibodi
mediat
opsonis
c
albican
cell
phagocytosi
kill
fungu
mous
macrophag
activ
mous
complement
cascad
vivo
model
combin
immunotherapi
anoth
attract
therapeut
strategi
antimannan
mab
shown
protect
effect
combin
immunotherapi
chemic
antifung
drug
administ
along
antibodi
exampl
mab
synergist
amphotericin
b
augment
therapeut
effect
fluconazol
mous
model
dissemin
candidiasi
exampl
demonstr
potenti
antifung
mab
clinic
set
use
drug
combin
power
strategi
enhanc
antifung
efficaci
abolish
drug
resist
major
antiinfect
monoclon
antibodi
develop
antivir
drug
main
focu
human
immunodefici
viru
hiv
neutralis
use
mice
immunis
sera
infect
human
sever
mab
develop
hiv
envelop
broadli
neutralis
across
subtyp
neutralis
mab
gener
result
human
infect
antibodi
respons
rang
epitop
variou
epitop
expos
bind
forsman
et
al
publish
gener
sever
high
affin
crossreact
vhh
neutralis
primari
isol
belong
subtyp
b
c
llama
immunis
recombin
belong
subtyp
b
result
phage
display
librari
pan
use
recombin
subtyp
b
c
competit
elut
strategi
use
employ
pan
isol
clone
shown
inhibit
bind
select
subtyp
propos
vhh
domain
inhibit
hiv
infect
interact
prior
engag
make
potenti
inhibitor
subsequ
famili
specif
phage
display
librari
construct
use
pbl
llama
immunis
recombin
deriv
tailor
use
degener
primer
base
nucleotid
sequenc
region
posit
neutralis
vhh
describ
result
picomolar
affin
vhh
shown
neutralis
broad
rang
viru
belong
subtyp
b
c
anoth
set
nanobodi
recognis
chemokin
receptor
isol
llama
immunis
phage
display
belong
gpcr
famili
therapeut
target
use
convent
antibodi
prove
unsuccess
probabl
tradit
antibodi
struggl
access
cryptic
buri
antigen
site
make
ligand
bind
pocket
receptor
surfac
play
import
role
stem
cell
physiolog
tissu
repair
inflamm
metastat
spread
cancer
also
serv
coentri
receptor
hiv
highli
potent
nanobodi
gener
use
whole
cell
immunis
cell
phage
display
librari
construct
biopan
behav
competit
antagonist
total
block
ligand
bind
inhibit
chemotaxi
entri
two
monoclon
antibodi
specif
recognis
capsid
protein
hepat
e
viru
isol
cdna
librari
construct
use
lymphocyt
isol
chimpanze
bone
marrow
chimpanze
experiment
infect
five
recognis
hepat
viru
hepat
e
phage
display
biopan
use
recombin
hev
protein
human
hev
strain
pakistani
strain
swine
hev
strain
us
strain
meng
gener
two
uniqu
mab
nanomolar
bind
affin
determin
biacor
analysi
heavi
chain
antihev
mab
sequenc
ident
human
famili
germ
line
segment
overal
ident
k
lightchain
sequenc
exhibit
ident
human
famili
germ
line
segment
mab
abl
neutralis
strain
hev
offer
protect
hev
infect
rhesu
monkey
author
highlight
signific
use
chimpanze
donor
antigen
prime
antibodi
repertoir
includ
possibl
infect
viral
pathogen
human
relev
reduc
immunogen
use
human
immunotherapi
earlier
studi
report
human
antibodi
recogn
self
chimpanze
immun
system
therebi
gener
littl
immunogen
compar
primat
halflif
human
mab
equival
estim
halflif
igg
human
schofield
colleagu
also
report
gener
four
monoclon
antibodi
hepat
viru
capsid
chimpanze
bone
marrow
deriv
cdna
librari
use
inactiv
whole
hav
capsid
strain
biopan
four
mab
neutral
strain
two
four
mab
also
neutral
diverg
strain
howev
actual
mechan
neutralis
remain
unclear
author
notic
fab
fragment
inhibit
viru
attach
cell
via
solubl
simian
cell
receptor
hav
develop
monoclon
fab
fragment
avail
public
domain
gener
vhh
immunis
llama
librari
hepat
b
surfac
antigen
hbsag
hepat
b
core
antigen
hbcag
explor
approach
inhibit
hbv
replic
therebi
tackl
viral
infect
result
vhh
fragment
express
intrabodi
target
antigen
exert
function
differ
compart
host
cell
cytoplasm
er
nucleu
intrabodi
shown
supress
secret
hbsag
hbcag
vitro
inhibit
viral
releas
mous
model
vhh
fragment
develop
use
anim
immunis
phage
display
technolog
includ
bind
rotaviru
hemagglutinin
reduc
viral
replic
influenza
viru
vhh
recognis
tail
infecti
phage
lactococcu
bacteria
list
relev
public
summaris
tabl
also
comprehens
list
antibodi
rais
viral
target
use
nonimmun
librari
present
recent
review
public
current
effect
treatment
respiratori
syncyt
viru
rsv
lower
respiratori
tract
infect
rsv
major
worldwid
caus
morbid
mortal
infant
young
children
immunocompromis
patient
elderli
treatment
remain
larg
support
rsvspecif
option
prophylaxi
limit
palivizumab
ablynx
trival
nanobodi
phase
ii
clinic
trial
treatment
rsv
infect
one
promis
candid
biolog
drug
develop
prevent
andor
treatment
rsv
infect
see
mazur
et
al
full
review
origin
isol
llama
deriv
immun
librari
monoval
domain
prior
reformat
multival
construct
use
genet
fusion
vhh
domain
demonstr
high
neutralis
potenc
rsva
rsvb
demonstr
superior
palivizumab
block
rsv
replic
camel
vhh
nanobodi
also
develop
treat
diseas
trypanosomiasi
african
sleep
sick
caus
parasit
trypanosoma
genu
trypanosoma
brucei
evolv
rang
sophist
immun
evas
mechan
includ
repeatedli
gener
variat
immunogen
variantspecif
surfac
glycoprotein
vsg
effici
internalis
antibodyvsg
complex
surfac
endocytosi
proteolysi
immunoglobulin
due
dens
packag
vsg
protein
surfac
trypanosoma
convent
antibodi
unabl
access
conserv
vsg
epitop
high
affin
nanobodi
clone
direct
toward
isotypespecif
conserv
epitop
vsg
protein
coat
isol
immunis
camelid
phage
display
vhh
librari
nanobodi
found
trypanolyt
vitro
vivo
show
potenti
high
affin
monoval
fragment
exert
cytotox
effect
parasit
even
absenc
fc
domain
author
demonstr
mode
action
domain
appear
includ
rapid
arrest
cell
mobil
blockag
endocytosi
flagellar
swell
collaps
mitochondri
membran
potenti
atp
exhaust
monoclon
antibodi
novel
smaller
antigen
bind
scaffold
present
attract
option
develop
new
therapi
molecular
drug
target
wide
rang
human
diseas
also
diagnost
due
specif
flexibl
book
chapter
abl
present
robust
combin
immunis
phage
display
technolog
rais
antibodi
specif
antigen
relev
number
infecti
diseas
public
health
interest
also
antigen
classifi
bioweapon
although
limit
associ
anim
immunis
especi
relat
ethic
issu
surround
anim
welfar
need
immunis
everi
antigen
interest
may
limit
access
anim
immunis
futur
howev
opinion
author
debat
regard
anim
use
research
purpos
substanti
assess
basi
riskbenefit
analysi
suitabl
